FOXC1 and neoplasm: Seventeen of the 22 multivariant studies were excluded either because they did not investigate the relationship between FOXC1 expression and cancer, did not categorize their results by tumor stage, or did not evaluate FOXC1 expression immunohistochemically (Figure 1).